Halozyme Therapeutics (HALO) and Eisai Inc. presented a scientific poster entitled, “Pegylated Recombinant Human Hyaluronidase PH20 (PEGPH20) Enhances …

Prohost Letter #388 TOPICS - 1. AN INDISPENSABLE SHORT INTRODUCTION 2. GENE EDITING 3. GENE THERAPY …

Today, the FDA advisory panel will discuss BioMarin (BMRN) product drisapersen for Duchenne muscular dystrophy based on documents released …

When we hear about a new approach that promises bringing in hopefulness in patients diagnosed with …

Exelixis (EXEL) received the first of the great news we expected to hear. Today, the U.S. Food …

To shareholders who were stupefied with an instigated selloff of Incyte’s (INCY) stock today, we say …

Prohost Letter #386 An Evaluation of Prohost Picks and Some Other Interesting Biotechnology Companies (Part 2) …

POSITIVE TOP-LINE RESULTS FROM A PHASE 2 TRIAL OF OMECAMTIV MECARBIL IN PATIENTS WITH CHRONIC HEART FAILURE …

– Exelixis submitted rolling NDA for cabozantinib. – Exelixis plans to complete the submission in the …

About Duchenne muscular Dystrophy treatments, bloggers tried to explain the reasons that led the FDA to …